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Abstract
Purpose: The most recent published guidelines on Clostridium difficile–associated diarrhea (CDAD) developed by the
Infectious Diseases Society of America (IDSA) were released in 2017 and outline its treatment based on severity of the disease
and recurrence; however, a clear first-line agent has not been recommended specifically for severe CDAD. Methods: This
retrospective chart review was approved by the institutional review board and consisted of three community hospitals and
one academic medical center. To be included, patients need to meet criteria for severe CDAD and receive at least 72 hours
of therapy. Patients received either oral vancomycin or fidaxomicin, in addition to other therapies for CDAD, and differences
in outcomes such as cost obtained from a common charge center, rates of recurrence, time to recurrence as measured at
time of positive to negative polymerase chain reaction (PCR) test, and mortality were assessed. Results: Of the 147 patients,
74 patients received fidaxomicin and 73 patients received oral vancomycin. The average hospitalization cost for patients
receiving fidaxomicin was $129,338.69 and for patients receiving vancomycin was $153,563.81 (P = .26). Recurrence rates
were lower with fidaxomicin compared with vancomycin (6.8% vs 17.6%; P = .047), and time to recurrence was longer with
fidaxomicin versus vancomycin, but not statistically significant (96.8 ± 45.9 days vs 63.2 ± 66.9 days; P = .321). Mortality,
length of stay in the intensive care unit, and overall length of stay were similar between the two therapies. Conclusions: In
the treatment of severe CDAD, recurrence rates were lower and time to recurrence was higher with fidaxomicin compared
with oral vancomycin. A clear financial benefit has yet to translate from these known findings.
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Introduction
Clostridium difficile–associated diarrhea (CDAD) involves
450,000 to 700,000 patient cases per year, contributes to an
increased hospital stay of 2.8 to 6.4 days, and costs approximately $3,006 to $15,397 per hospitalization, subsequently
leading to a cost to the health care system of $4.8 billion per
year.1-3 The symptoms and complications associated with
CDAD range from pseudomembranous colitis to ileus or
toxic megacolon and potentially the need for colectomy.1,2 In
addition, the incremental risk of death associated with CDAD
is approximately 5% to 11%.4 Risk factors for developing
CDAD include patients who are elderly, have received proton pump inhibitors, have received chemotherapy, possess
concomitant human immunodeficiency virus (HIV), or have
received broad-spectrum antibiotics. The highest risk groups
are oncology patients or patients receiving hematopoietic
stem-cell transplants.1-3,5,6

The most recent guidelines on CDAD developed by the
Infectious Diseases Society of America (IDSA) and the
Society for Healthcare Epidemiology of America (SHEA)
were updated in 2017 and outline the treatment of CDAD
based on severity of the disease and recurrence. The panel
defined severe CDAD as patients presenting with leukocytosis (≥15,000 cells/mm3) or serum creatinine level ≥1.5
times the premorbid level. Initial treatment for severe disease
involves oral vancomycin at a dose of 125 mg 4 times daily
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for 10 to 14 days or fidaxomicin 200 mg oral twice daily for
10 days. If ileus, shock, or megacolon is noted, the CDAD
is then defined as severe, complicated disease and vancomycin at a dose of 500 mg by mouth or nasogastric tube,
plus metronidazole 500 mg intravenously every 8 hours, is
recommended; however, fidaxomicin is not recommended
for this use.1
Fidaxomicin (Dificid)7 is a macrocyclic antibiotic that
was approved by the Food and Drug Administration for the
treatment of CDAD in 2011.7 The mechanism by which
fidaxomicin kills C difficile is through inhibition of the bacteria’s RNA polymerase that is involved in protein synthesis.
Fidaxomicin has a limited spectrum of activity against
microbes; it possesses bactericidal activity against Grampositive anaerobes, including C difficile. Similar to oral vancomycin, fidaxomicin produces extremely low concentrations
in the serum and undetectable concentrations in the urine,
demonstrating that it is not systemically absorbed.7-10
Specifically, this agent falls into the treatment of recurrence,
based on expert reviews and clinical data; however, there is
little evidence on the treatment of severe CDAD.11-13 Finally,
the agent is immensely expensive; however, if clinical endpoints such as recurrence rates and time to recurrence are
better with fidaxomicin, it may off-set the financial implications for utilizing the agent.
This study was conducted to evaluate the financial utility of fidaxomicin compared with oral vancomycin in the
setting of severe CDAD, given the lack of data available on
the subject.

Methods
This was a retrospective chart review conducted from
January 1, 2012, to December 31, 2014, of patients admitted
to the hospital and identified with a positive C difficile test at
3 community hospitals and 1 academic medical center in a
single health system. After patients were determined to have
a positive test result, they were screened for inclusion criteria. To be included in the study, patients must have received
72 hours of medication, met criteria for severe CDAD as
established by the IDSA/SHEA guidelines, and been ≥18
years of age. Patients were excluded if they had diverticulitis, Crohn disease, ulcerative colitis, or irritable bowel syndrome. After patients met criteria for inclusion, they were
assigned to groups based on which CDAD therapy they
received for >72 hours. If a patient was switched to another
therapy or received <72 hours, they were excluded.
Baseline characteristics were collected from initiation of
CDAD therapy to classify patient’s disease severity, in addition
to established risk factors for developing CDAD, such as
broad-spectrum antibiotics within the last 90 days or concurrent, previous chemotherapy and/or radiation within the last 90
days, immunosuppression (HIV or solid organ transplant), and
advanced age (age >64 years). Adjunctive therapies for CDAD
such as rifaximin, intravenous immunoglobulin, tigecycline,

metronidazole, rectal vancomycin, and stool transplant were
collected and quantified. These therapies could be used specifically for CDAD or other conditions the patient had during
their encounter. The primary outcome of this study was to
compare the associated hospital charges for patients receiving
fidaxomicin versus oral vancomycin. Financial reports were
obtained and included charges to patients for room stay, the
use of mechanical ventilation or supplemental oxygen, medications including as-needed medications, radiological scans,
and laboratory tests. Secondary outcomes were length of stay
(LOS), intensive care unit (ICU) admission, ICU LOS, episodes of recurrence, time to recurrence, and mortality. Patients
were classified as having recurrence if they were subsequently
readmitted with a positive C difficile test. Statistical tests that
were used to analyze baseline characteristics and study outcomes were the chi square, Fisher exact test, or Student t test
where appropriate by means of the SPSS software. The primary outcome of cost was assessed for normal distribution
and analyzed with a Student t test. The secondary outcomes
were also assessed for normal distribution and analyzed with
chi-square or Fisher exact test where appropriate for nominal
data, and Mann-Whitney U or a Student’s t test for continuous
variables where appropriate based on distribution. The study
received institutional review board approval through the
University of Tennessee and did not receive any financial
grants or support from outside sources.

Results
Overall, 377 patients were screened for inclusion with 147
meeting inclusion criteria. Of the 147 patients meeting inclusion criteria, 73 patients received vancomycin and 74 patients
received fidaxomicin as their primary CDAD treatment (see
Figure 1). Baseline demographics between the two groups
were similar in regard to characteristics (Table 1), risk factors (Table 2), and adjunctive therapies (Table 3); however,
there were a larger number of African American patients,
patients with larger WBC elevations, solid organ transplant
recipients, and prior receipt of broad-spectrum antibiotics in
the oral vancomycin arm compared with the fidaxomicin
arm. On average, patients were middle-aged, African
American, and female. Furthermore, patients were most
likely to have chronic kidney disease, been on a form of
hemodialysis, and received concurrent broad-spectrum antibiotics. There were no differences between the two treatment
groups in regard to adjunctive therapies that may have made
an impact on a patient’s eradication of C difficile.
The primary outcome of hospital charges incurred to
patients during their hospitalization was lower with fidaxomicin compared with oral vancomycin ($54,172.96 ±
53,385 vs $64,138.09 ± 54,542.84); however, this finding
was not statistically significant (P = .26) (Table 4). The LOS
for the patient’s hospitalization (22.6 days vs 21.5 days; P =
.82) and ICU LOS (10.4 days vs 13.0 days; P = .95) were no
different between patients receiving fidaxomicin versus oral
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Excluded (n=230)
-Not severe CDAD (n=173)
-Metronidazole
monotherapy (n=41)
-< 72 hours of active drug
(n= 9)
-Irritable bowel syndrome
(n=3)
-Ulcerative colitis (n=3)

Admissions Screened for
Inclusion
(n=377)

Admissions Included
(n=147)

Oral vancomycin
(n=73)

Fidaxomicin
(n=74)

Figure 1. Patient allocation.

Note. CDAD = Clostridium difficile–associated diarrhea.

Table 1. Baseline Demographics.
Demographics
Age (years, SD)
Female (n, %)
African American (n, %)
White blood cell count (cells/mm3, SD)
Serum creatinine (mg/dL, SD)
Ileus (n, %)
Dialysis (n, %)
Chronic Kidney Disease (n, %)

Oral vancomycin (n = 73)

Fidaxomicin (n = 74)

P value

61 ± 17
38 (52)
51 (70)
19.6 ± 15.4
3.0 ± 2.7
4 (5.5)
15 (20.5)
26 (35.6)

58 ± 19
40 (54)
41 (55)
15.4 ± 10.5
3.4 ± 3.3
1 (1.4)
17 (23)
18 (24.3)

.31
.89
.09
.06
.42
.21
.84
.15

vancomycin, respectively. With respect to reducing recurrence and prolonging the eradication of C difficile, fidaxomicin was found to be more effective than oral vancomycin in
the setting of severe CDAD. The incidence of recurrence was
6.8% with fidaxomicin (5 of 74 patients) and 17.6% with
oral vancomycin (13 of 73 patients), which was a statistically
significant finding (P = .047). The time to recurrence of C
difficile infection was longer with fidaxomicin compared
with oral vancomycin (96.8 ± 45.9 days vs 63.2 ± 66.9
days; P = .321). Finally, there was no difference in mortality
between the two treatments with 9 deaths in the oral vancomycin group and 7 deaths in the fidaxomicin group (P = .6).

Discussion
This was a retrospective chart review comparing fidaxomicin with oral vancomycin in the setting of severe CDAD.

Since its approval in 2011, fidaxomicin utilization has
evolved from a second-line agent to a concomitant option for
the first-line treatment of CDAD alongside oral vancomycin.
After reviewing the published data for treatment of severe
CDAD, or now fulminant CDAD as defined by the update,
there is still minimal data for this specific indication, and
even less regarding monetary benefits.1,10 A cost-effective
analysis conducted by Nathwani and colleagues took the
known outcomes from previous studies with fidaxomicin
and CDAD and attempted to determine whether these outcomes also benefited patients and the health care system
financially.11 The investigators utilized a 1-year time horizon
Markov model to determine incremental cost-effectiveness
ratios that were further determined by adjusted cost per qualityadjusted life years and cost per recurrence avoided. Overall,
the final analysis found similar total costs for fidaxomicin
and vancomycin but differences in clinical outcomes that
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Table 2. Risk Factor Demographics.
Risk factor

Oral vancomycin (n = 73)

Fidaxomicin (n = 74)

P value

2 (2.7)
10 (13.7)
9 (12.3)
0
2 (2.7)
10 (13.7)
57 (78.1)

2 (2.7)
13 (17.6)
5 (6.8)
1 (1.4)
4 (5.4)
4 (5.4)
52 (70.3)

1
.65
.28
1
.68
.1
.35

Human immunodeficiency virus (n, %)
Malignancy (n,%)
Solid organ transplant (n,%)
Hematopoetic stem cell (n, %)
Prior chemotherapy (n, %)
Previous broad-spectrum antibiotics (n, %)
Broad-spectrum antibiotics (n, %)

Table 3. Adjunctive Therapies.
Treatment
Metronidazole (n, %)
Rifaximin (n, %)
Intravenous immunoglobulin (n, %)
Stool transplant (n, %)
Tigecycline (n, %)
Probiotics (n, %)

Oral vancomycin (n = 73)

Fidaxomicin (n = 74)

P value

51 (69.9)
1 (1.4)
0
0
13 (17.8)
13 (17.8)

43 (58.1)
1 (1.4)
0
1 (1.4)
18 (24.3)
13 (17.6)

.17
1
NA
1
.42
1

Table 4. Study Outcomes.
Outcome
Length of stay (days, SD)
ICU admissions (n, %)
ICU length of stay (days, SD)
Recurrence (n, %)
Time to recurrence (days, SD)
Mortality (n, %)

Oral vancomycin (n = 73)

Fidaxomicin (n = 74)

21.5 ± 15.7
46 (63)
13.0 ± 10.7
13 (17.8)
63.2 ± 64.3
9 (12.3)

22.6 ± 37.1
36 (48.7)
10.4 ± 7.9
5 (6.8)
96.8 ± 41.0
7 (9.5)

P value
.82
.1
.95
.047
.0002
.6

Note. ICU = intensive care unit.

resulted in benefits in incremental cost-effectiveness ratios
for severe CDAD and in patients with multiple recurrences.
From the captured charges to patients, we found an average
cost of $54,172.96 ± 53,385 compared with an average
cost of $64,138.09 ± 54,542.84, which was not statistically
significant. This is a different finding from the cost-effective analysis; however, it should be noted the large degree
of standard deviation that makes these results difficult to
apply.
The first study of fidaxomicin published by Louie and
colleagues excluded patients with severe CDAD and
attempted to establish efficacy for fidaxomicin in the
highly virulent strains of C difficile (NAP1/BI/027).12 The
investigators enrolled 629 patients, with 548 patients overall that experienced a clinical cure and based on that, were
evaluable for recurrence. The patients in the study were
predominantly older females who were treated as outpatients. Overall, the study found that fidaxomicin was associated with lower rates of recurrence when compared with
oral vancomycin (15.4% vs 25.3%; P = .005). The

difference with rates of recurrence, however, was lost
when examined in the group of patients who had data
available on NAP1/BI/027, with similar rates of recurrence
between fidaxomicin and vancomycin (24.4% vs 23.6%).
When this outcome was analyzed in other strains of C difficile, the rates of recurrence were lower with fidaxomicin
compared with vancomycin (7.8% vs 25.5%; P < .001)
and the relative risk for recurrence in these strains was 3.3
times higher with patients receiving vancomycin. A study
by Cornely and colleagues was conducted to determine
whether there were benefits to using fidaxomicin in various subpopulations over oral vancomycin.13 From the large
population pulled from the registry the investigators utilized, 91 patients with severe CDAD were evaluable for
rates of recurrence and 124 similar patients were evaluable
for response rates. In terms of rates of recurrence in severe
CDAD, fewer patients experienced recurrence of CDAD
with fidaxomicin compared with oral vancomycin (4/48
patients, 8.3% vs 14/43 patients, 32.6%; P = N/A). There
were also more patients with fidaxomicin achieving longer
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sustained response rates compared with oral vancomycin
(44/63 patients, 69.8% vs 29/61 patients, 47.5%; P =
.012). This large analysis also did not find differences in
treatment outcomes between fidaxomicin and oral vancomycin in the BI/027 strains as well.12 Our analysis found
similar results in regard to rates of recurrence favoring
fidaxomicin over oral vancomycin (6.8 % vs 17.6%; P =
.047) in the setting of severe CDAD. Because our institution does not test for the NAP1/BI/027 strain at the time,
we were not able to analyze whether this would impact
outcomes in the setting of severe CDAD. From the second
analysis, it appears that the strain of C difficile does not
impact the outcomes of therapy in severe CDAD.
There are several limitations to this study that need to
be considered in light of these findings. The first is that
this was a small retrospective study performed at multiple
hospitals within a single health system. Including patients
at other health care systems would increase the applicability of our results; however, it also introduces a potential
confounder in consistent standard of care. Patients were
screened for severe or fulminant CDAD to be included in
the study, but other markers such as the Acute Physiologic
Assessment and Chronic Health Evaluation (APACHE) or
Sequential Organ Failure Assessment (SOFA) might have
been beneficial to analyze as baseline demographics. At
our institution, we do not routinely test for specific strains
of C difficile; therefore, these data were not available to be
analyzed. Previous studies have also assessed the role of
fidaxomicin in highly virulent strains such as NAP1/
BI/027, which have shown no difference between fidaxomicin and oral vancomycin, making this limitation negligible.11-13 The data that we obtained to assess any cost
differences associated with the two treatments were also
only reflective of the charges to the patient and would not
be reflective of real-world pharmacoeconomics and may
have led to the large standard deviations in that analysis.
Finally, we were unable to assess compliance in patients
who were discharged on outpatient therapy due to the retrospective nature of the study, nor the presence of signs or
symptoms of recurrence in the outpatient setting.

Conclusion
The role of fidaxomicin in CDAD is mostly clear in that it
reduces the incidence of recurrence and provides a prolonged
response; however, the role of fidaxomicin in severe CDAD
has yet to be determined. This retrospective analysis demonstrated that there is no financial benefit with using fidaxomicin in severe CDAD, but there might be a role in reducing the
rates of recurrence. Further studies are needed in general, as
well as pharmacoeconomic analysis, to determine whether
the differences in recurrence can impact future hospitalizations and thus reducing cost.
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